HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL

CARMEN HERNANDEZ-CARDENAS; IRERI THIRION-ROMERO; NORMA E RIVERA-MARTINEZ; PATRICIA MEZA-MENESES; ARANTXA REMIGIO-LUNA; Rogelio Perez-Padilla.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21250371

Documentos relacionados

  1. Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial.
  2. [ECMO cannulation for COVID-19].
  3. [Psychiatric symptoms and COVID-19: results of a national case register].
  4. [Vitamin D and COVID-19: a communication far from reality].
  5. [Social Inequalities and COVID-19: Social-Epidemiological Perspectives on the Pandemic].
  6. [Chemosensory disorders in Covid-19: Pathomechanisms and clinical relevance].
  7. [COVID-19: epidemiology and clinical facts].
  8. [Alopecia and COVID-19: possible etiopathogenetic variants and therapeutic approach].
  9. [Salmonella Bacteremia Accompanying COVID-19: The First Salmonella Co-Infection in the World Unrelated to Pakistan].
  10. [Prognostic factors in an individualised approach to non-pharmacological therapy of COVID-19: from oxygen and mechanical ventilation to extracorporeal membrane oxygenation].